Page 19 - DIAGEN

primeFISH Products Hermatology
HEMATOLOGY

PANEL

17-069 IGH-FGFR3 t(4;14)

The FGFR3 (fibroblast growth factor receptor 3) gene is are observed in approximately 15-20% of MM patients.
located in the 4pl6.3 region, and the IGH (immunoglobulin Breakpoints for the 4Pl6.3 locus are located between
heavy locus) is located in the 14q32.33 region. FGFR3 the FGFR3 gene and the 5’ end of the NSD2 gene. The
encodes a receptor tyrosine kinase that regulates the t(4;14)(pl6.3;q32.3) translo cation is associated with up-
downstream signaling chain after ligand binding. Fusion regulation of FGFR3 and myeloma NSD2 (also known as
of several part ner genes (including the IGH locus), often MMSET) portion protein. Patients with the FGFR3/IGH
found in multiple myeloma (MM), can lead to ligand-in translocation show an overall poor prognosis, which is
dependent activation of the tyrosine kinase of the re- only partially alleviated by the use of the newer agents
sulting FGFR3 fusion protein. FGFR3/IGH trans locations bortezomib and lenalidomide.

4q16.3
TRANSLOCATION

SHGC-68972 RH91968
5' 3'
Gen Tel
FGFR3
NORMAL
726 kb

RH65489 SHGC-144461
3' 5' TRANSLOCATION
Gen Tel
IGH

14q12.33 1.5 mb

TRANSLOCATION
(Not to scale)

References
Kalff A & Spencer A (2012) Blood Cancer J. 7: e89.
Walker BA, et al. (2013) Blood 121: 3413-19 www.diagen.com.tr
Arsham, MS., Barch, MJ. and Lawce HJ. (eds.) (2017) The AGT Cytogenetics Laboratory Manual. New
Jersey: John Wiley & Sons Inc.

info@diagen.com.tr PRODUCT CATALOGUE 19